Feedback Share Discussion Threads

[impvesta] 06/10/2015 14:16

This looks a potentially very exciting company and I've been DMOR to assess this as a possible investment. Looks as if I am a few days late (!!) but I am trying to get my head round the company structure.

If I understand correctly the company does not have any executive directors, all three directors being NEDs. Is this correct? Who is actually running the company?

From a shareholding control point of view Trevor Brown and Tom Charlton can clearly call the shots as, according to the RNS on 3rd June, they own 51% of the company between them (Brown 27.29%, Charlton 24.53%).

Do this BB's regulars see either of these points as an issue? I'm interested in your views.

Impvesta

[someuwin] 06/10/2015 14:14

...Wow - this has amazing potential.

[someuwin] 06/10/2015 14:02

Prostate cancer

Lung cancer

Research sale to China

positive results from renal cell cancer trial

JV with Quibim.

Kidney stones / Urology product.

Research sale to Canada

University of Texas

etc etc.

[lr2] 06/10/2015 13:51

3.07p - 3.475p (max 25k available online).

Britstox, "First we take Manhattan then we take Berlin..."

[cheaky monkey] 06/10/2015 13:48

The spread is a killer though!

[britstox] 06/10/2015 13:27

Next stop global domination? ; )

[britstox] 06/10/2015 13:27

Well LR2 and Blueball...what can I say? Happy is not the word. It's finally getting the recognition it deserves. We were right!

[blueball] 06/10/2015 13:24

Surprise Mike Walters hasn't picked up on this one I used to be a subscriber in the past.

[someuwin] 06/10/2015 13:15

There's a lot to like here - not least the very low mkt cap.

[blueball] 06/10/2015 12:45

Bought some more @3.14p.

largely because if the Ichimoku Kumo breakout last night.

[someuwin] 06/10/2015 11:21

Looks very good.

[kenwrong] 06/10/2015 10:29

The Quibim tie up and NHS alert should prove once and for all that this Feedback is no one hit wonder. Thanks Zuess, as you say these markets will all be taking the Texrad software which should then become the benchmark standard. Malcolm Stacy has written about Feedback again this morning at Shareprophets quote "It doesn't look to this old punter that the market has woken up to the fact that the technology, known as TexRAD, is so useful" unquote - Exciting times for us all!!

[lr2] 06/10/2015 10:16

Thanks Blueball.

I posted the NHS alert on here last Friday night (post #865) and nobody seemed to register the importance of it other than Britstox. Just as well Feedback got around to announcing the news today as my post had no effect on the share price. :)

[blueball] 06/10/2015 10:12

Yes well done LR2 spot on with your post 865.

[zeuss1] 06/10/2015 10:11

So we have a global prostate cancer market estimated to be worth some $50bn in 2017. Now the NHS have flagged TexRAD's potential as a tool for assessing patients with lung cancer. There are multiple potential other applications for TexRAD that will no doubt feature in Feedback's development, but for now this is a very exciting little company with a potential life saving technology that is still worth just £4.5m.

[blueball] 06/10/2015 09:58

My target is 5p here wont be long according to the news today.

[blueball] 05/10/2015 19:08

stay long.

[blueball] 05/10/2015 19:08

Ichimoku Kumo break-out.

[zeuss1] 05/10/2015 09:33

So hot on the heels of the Stone Checker jv between Feedback and UK Urology, we have another much larger marketplace application for Texrad. A new jv with Quibim called Prostate Checker Ltd hxxp://prostatechecker.co.uk sees Texrad adapted for use by clinicians in diagnosing and assessing treatment options for prostate cancer. This new announcement dwarfs the Stone Checker jv in terms of its global potential, and should see brokers covering Feedback (FDBK) re rate the stock to take in this new potential revenue stream.

[blueball] 04/10/2015 11:05

Zac Mir has a 3.5p target.